Top-down MS for rapid methionine oxidation site assignment in filgrastim
暂无分享,去创建一个
Johann Holzmann | J. Holzmann | Anna Hausberger | Alfred Rupprechter | Hansjoerg Toll | Anna Hausberger | Hansjoerg Toll | A. Rupprechter
[1] Leonid Zamdborg,et al. The emerging process of Top Down mass spectrometry for protein analysis: biomarkers, protein-therapeutics, and achieving high throughput. , 2010, Molecular bioSystems.
[2] M. Mann,et al. Proteomics on an Orbitrap Benchtop Mass Spectrometer Using All-ion Fragmentation , 2010, Molecular & Cellular Proteomics.
[3] F. Sörgel,et al. Physicochemical and Biologic Comparability of a Biosimilar Granulocyte Colony-Stimulating Factor with its Reference Product , 2010, BioDrugs.
[4] N. Kearney,et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.
[5] N. Kunishima,et al. Atomic structure of the GCSF–receptor complex showing a new cytokine–receptor recognition scheme , 1999, Nature.
[6] M. Aapro,et al. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia , 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[7] V. Katta,et al. Structural characterization of intact antibodies by high-resolution LTQ Orbitrap mass spectrometry. , 2009, Journal of mass spectrometry : JMS.
[8] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[9] Zhongqi Zhang,et al. Characterization of variable regions of monoclonal antibodies by top-down mass spectrometry. , 2007, Analytical chemistry.
[10] Bernhardt L. Trout,et al. Effects of Antioxidants on the Hydrogen Peroxide-Mediated Oxidation of Methionine Residues in Granulocyte Colony-Stimulating Factor and Human Parathyroid Hormone Fragment 13-34 , 2004, Pharmaceutical Research.
[11] J. Nemunaitis. A Comparative Review of Colony-Stimulating Factors , 1997, Drugs.
[12] Scott A McLuckey,et al. 'Top down' protein characterization via tandem mass spectrometry. , 2002, Journal of mass spectrometry : JMS.
[13] Richard D. LeDuc,et al. Mapping Intact Protein Isoforms in Discovery Mode Using Top Down Proteomics , 2011, Nature.
[14] L. F. Waanders,et al. Top-down Protein Sequencing and MS3 on a Hybrid Linear Quadrupole Ion Trap-Orbitrap Mass Spectrometer*S , 2006, Molecular & Cellular Proteomics.
[15] Peter Oefner,et al. BIOANALYSIS , 2008, Electrophoresis.
[16] Bernhardt L Trout,et al. Molecular dynamics simulations and oxidation rates of methionine residues of granulocyte colony-stimulating factor at different pH values. , 2004, Biochemistry.
[17] Bernhardt L Trout,et al. Comparative oxidation studies of methionine residues reflect a structural effect on chemical kinetics in rhG-CSF. , 2006, Biochemistry.
[18] M. Mccamish,et al. The State of the Art in the Development of Biosimilars , 2012, Clinical pharmacology and therapeutics.
[19] P. Bondarenko,et al. Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-orbitrap mass spectrometer , 2009, Journal of the American Society for Mass Spectrometry.
[20] David C. Dale,et al. Colony-Stimulating Factors for the Management of Neutropenia in Cancer Patients , 2002, Drugs.
[21] D. Figeys,et al. Advancements in top-down proteomics. , 2012, Analytical chemistry.
[22] W. Bretz,et al. Red Marine Algae Lithothamnion calcareum Supports Dental Enamel Mineralization , 2023, Marine drugs.
[23] J. Beijnen,et al. Oxidation of recombinant methionyl human granulocyte colony stimulating factor. , 1998, Journal of pharmaceutical and biomedical analysis.
[24] B. Warrack,et al. Characterization of protein therapeutics by mass spectrometry: recent developments and future directions. , 2011, Drug discovery today.
[25] M. Macht. Mass spectrometric top-down analysis of proteins. , 2009, Bioanalysis.
[26] D Eisenberg,et al. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Škrlin,et al. Correlation of liquid chromatographic and biological assay for potency assessment of filgrastim and related impurities. , 2010, Journal of pharmaceutical and biomedical analysis.
[28] E. Veltri,et al. Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF. , 2012, Future oncology.
[29] I. Campbell,et al. Secondary structure and backbone dynamics of human granulocyte colony-stimulating factor in solution. , 1994, Biochemistry.
[30] Daniel I. C. Wang,et al. Effects of Excipients on the Hydrogen Peroxide-Induced Oxidation of Methionine Residues in Granulocyte Colony-Stimulating Factor , 2004, Pharmaceutical Research.
[31] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[32] D. Metcalf. Granulocyte-macrophage colony-stimulating factors , 1985, Cell.
[33] Fred W. McLafferty,et al. Top-down identification and characterization of biomolecules by mass spectrometry , 2008, Journal of the American Society for Mass Spectrometry.
[34] G Shimamoto,et al. Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity. , 1999, Archives of biochemistry and biophysics.
[35] P. Gascón. Presently available biosimilars in hematology-oncology: G-CSF , 2012, Targeted Oncology.
[36] Matthew T. Mazur,et al. A Platform for Characterizing Therapeutic Monoclonal Antibody Breakdown Products by 2D Chromatography and Top-Down Mass Spectrometry , 2012, The AAPS Journal.